Koran says that the small number of subjects in the study makes it impossible to know with certainty whether the results of the trial are really indicative of the effectiveness of escitalopram.
"For some people, I think these drugs really do work. And for others, maybe not, but until you have large studies you can't tease that out," he said.
Koran emphasized that the results of the clinical trial are not definitive, and some people may be helped by therapy involving medication. For others, receiving psychological treatment, perhaps in combination with medication, may prove most effective. But regardless, he said, "People with this disorder should definitely seek treatment."
This study was funded by Forest Laboratories, which makes and markets Lexapro. Koran has served as a paid speaker for Forest Laboratories, as has second author Elais Aboujaoude, MD, clinical assistant professor of psychiatry and behavioral sciences and director of Stanford's Impulse Control Clinic. Nona Gamel, clinical research manager, was also a co-author on the study.
Stanford University Medical Center integrates research, medical education and patient care at its three institutions -- Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.